

Mercedes Beltrán González

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2781656/publications.pdf>

Version: 2024-02-01

204
papers

7,134
citations

50170

46
h-index

85405

71
g-index

215
all docs

215
docs citations

215
times ranked

6403
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Evaluation of 2-Amino-7-Fluorophenazine 5,10-Dioxide Polymeric Micelles as Antitumoral Agents for 4T1 Breast Cancer. <i>Polymers</i> , 2022, 14, 71.	2.0	2
2	Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay. <i>Bioorganic Chemistry</i> , 2020, 94, 103372.	2.0	2
3	New aryloxyquinone derivatives with promising activity on <i>Trypanosoma cruzi</i> . <i>Archiv Der Pharmazie</i> , 2020, 353, e1900213.	2.1	12
4	In vitro and in silico evaluations of new aryloxy-1,4-naphthoquinones as anti- <i>Trypanosoma cruzi</i> agents. <i>Medicinal Chemistry Research</i> , 2020, 29, 665-674.	1.1	11
5	Selective Hypoxia Cytotoxin 7-Fluoro-2-Aminophenazine 5,10-Dioxide: Toward Candidate Drug Stage in the Drug Development Pipeline. <i>ChemistrySelect</i> , 2019, 4, 9396-9402.	0.7	5
6	Identification of N-Oxide-Containing Aromatic Heterocycles as Pharmacophores for Rumen Fermentation Modifiers. <i>Metabolites</i> , 2019, 9, 62.	1.3	1
7	Formation of dendrimer-guest complexes as a strategy to increase the solubility of a phenazine N, N-dioxide derivative with antitumor activity. <i>Heliyon</i> , 2019, 5, e01528.	1.4	12
8	Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides. <i>Environmental Toxicology and Pharmacology</i> , 2019, 69, 9-15.	2.0	8
9	Novel coumarins active against <i>Trypanosoma cruzi</i> and toxicity assessment using the animal model <i>Caenorhabditis elegans</i> . <i>BMC Pharmacology & Toxicology</i> , 2019, 20, 76.	1.0	7
10	Polypharmacology in the Treatment of Chagas Disease. <i>Current Medicinal Chemistry</i> , 2019, 26, 4476-4489.	1.2	10
11	Inhibition of LDL oxidation and inflammasome assembly by nitroaliphatic derivatives. Potential use as anti-inflammatory and anti-atherogenic agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 178-186.	2.6	3
12	Slowed Development of Natural Products for Chagas Disease, how to Move Forward?. , 2018, , .		2
13	Novel and Selective <i>Rhipicephalus microplus</i> Triosephosphate Isomerase Inhibitors with Acaricidal Activity. <i>Veterinary Sciences</i> , 2018, 5, 74.	0.6	13
14	Looking for combination of benznidazole and <i>Trypanosoma cruzi</i> -triosephosphate isomerase inhibitors for Chagas disease treatment. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2018, 113, 153-160.	0.8	12
15	Synthesis and in vivo proof of concept of a BODIPY-based fluorescent probe as a tracer for biodistribution studies of a new anti-Chagas agent. <i>RSC Advances</i> , 2017, 7, 7983-7989.	1.7	9
16	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative <i>trypanosoma cruzi</i> drugs: Computational screening from neural network, synthesis and in vivo biological properties. <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 223-234.	2.6	9
17	Development, validation and application of a GC-MS method for the simultaneous detection and quantification of neutral lipid species in <i>Trypanosoma cruzi</i> . <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 225-232.	1.2	9
18	3-(Benzyloxy)-1-(5-[¹⁸ F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. <i>Future Medicinal Chemistry</i> , 2017, 9, 983-994.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Multi-Anti-Parasitic Activity of Arylidene Ketones and Thiazolidene Hydrazines against <i>Trypanosoma cruzi</i> and <i>Leishmania</i> spp.. <i>Molecules</i> , 2017, 22, 709.	1.7	25
20	Potent and Selective Inhibitors of <i>Trypanosoma cruzi</i> Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity. <i>ChemMedChem</i> , 2016, 11, 1328-1338.	1.6	38
21	New hybrid bromopyridine-chalcones as in vivo phase II enzyme inducers: potential chemopreventive agents. <i>MedChemComm</i> , 2016, 7, 2395-2409.	3.5	8
22	Synthesis and biological evaluation of quinoxaline di-N -oxide derivatives with in vitro trypanocidal activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 903-906.	1.0	16
23	In vivo phase II-enzymes inducers, as potential chemopreventive agents, based on the chalcone and furoxan skeletons. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1665-1674.	1.4	18
24	Identification of Chalcones as <i>Fasciola hepatica</i> Cathepsin L Inhibitors Using a Comprehensive Experimental and Computational Approach. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004834.	1.3	23
25	Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes. <i>Inflammation and Allergy: Drug Targets</i> , 2015, 14, 19-28.	1.8	1
26	3-H-[1,2]Dithiole as a New Anti- <i>Trypanosoma cruzi</i> Chemotype: Biological and Mechanism of Action Studies. <i>Molecules</i> , 2015, 20, 14595-14610.	1.7	11
27	Preparation and Biological Evaluation of ^{99m} Tc-Labelled Phenazine Dioxides as Potential Tracers for Hypoxia Imaging. <i>Current Radiopharmaceuticals</i> , 2015, 8, 56-61.	0.3	2
28	Expanding the family of heteroleptic oxidovanadium(IV) compounds with salicylaldehyde semicarbazones and polypyridyl ligands showing anti- <i>Trypanosoma cruzi</i> activity. <i>Journal of Inorganic Biochemistry</i> , 2015, 147, 116-125.	1.5	31
29	Molecular docking and molecular dynamics simulation studies of <i>Trypanosoma cruzi</i> triosephosphate isomerase inhibitors. Insights into the inhibition mechanism and selectivity. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 58, 40-49.	1.3	30
30	Design, synthesis and in vitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 100, 24-33.	2.6	18
31	A new ruthenium cyclopentadienyl azole compound with activity on tumor cell lines and trypanosomatid parasites. <i>Journal of Coordination Chemistry</i> , 2015, 68, 2923-2937.	0.8	37
32	New aryloxy-quinone derivatives as potential anti-Chagasic agents: synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis. <i>RSC Advances</i> , 2015, 5, 65153-65166.	1.7	24
33	Development of bis-thiazoles as inhibitors of triosephosphate isomerase from <i>Trypanosoma cruzi</i> . Identification of new non-mutagenic agents that are active in vivo. <i>European Journal of Medicinal Chemistry</i> , 2015, 100, 246-256.	2.6	37
34	Searching phase II enzymes inducers, from Michael acceptor-[1,2]dithiolethione hybrids, as cancer chemopreventive agents. <i>Future Medicinal Chemistry</i> , 2015, 7, 857-871.	1.1	12
35	New hits as phase II enzymes inducers from a focused library with heteroatom-heteroatom and Michael-acceptor motives. <i>Future Science OA</i> , 2015, 1, FSO20.	0.9	4
36	Identification of a New Amide-Containing Thiazole as a Drug Candidate for Treatment of Chagas' Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1398-1404.	1.4	39

#	ARTICLE	IF	CITATIONS
37	In Vivo Anti-Trypanosoma cruzi Activity of Hydro-Ethanollic Extract and Isolated Active Principles from Aristeguetia glutinosa and Mechanism of Action Studies. <i>Molecules</i> , 2014, 19, 8488-8502.	1.7	20
38	Initial studies on mechanism of action and cell death of active N-oxide-containing heterocycles in Trypanosoma cruzi epimastigotes in vitro. <i>Parasitology</i> , 2014, 141, 682-696.	0.7	9
39	New chemotypes as Trypanosoma cruzi triosephosphate isomerase inhibitors: a deeper insight into the mechanism of inhibition. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 198-204.	2.5	19
40	A serendipitous one-step conversion of 3H-1,2-dithiole-3-thione to (E)-3-[1-(alkylthio)alkylidene]-3H-1,2-dithiole: an experimental and theoretical study. <i>Molecular Diversity</i> , 2014, 18, 285-294.	2.1	7
41	Trypanosoma cruzi chemical proteomics using immobilized benzimidazole. <i>Experimental Parasitology</i> , 2014, 140, 33-38.	0.5	14
42	Arylnitroalkenes as scavengers of macrophage-generated oxidants. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 31-40.	2.6	8
43	Optimization of Antitrypanosomatid Agents: Identification of Nonmutagenic Drug Candidates with in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3984-3999.	2.9	40
44	Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3919-3922.	1.0	13
45	Evaluation of different PAMAM dendrimers as molecular vehicle of 1,2,4-triazine N-oxide derivative with potential antitumor activity. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2014, 79, 65-73.	0.9	8
46	Mutagenicity of N-oxide Containing Heterocycles and Related Compounds: Experimental and Theoretical Studies. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 1374-1387.	1.0	18
47	Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 324-334.	2.6	44
48	Biotransformation of Phenazine 5,10-Dioxides under Hypoxic Conditions as an Example of Activation of Anticancer Prodrug: An Interdisciplinary Experiment for Biochemistry or Organic Chemistry. <i>Journal of Chemical Education</i> , 2013, 90, 1388-1391.	1.1	4
49	1,2,4-thiadiazol-5(4H)-ones: a new class of selective inhibitors of Trypanosoma cruzi triosephosphate isomerase. Study of the mechanism of inhibition. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2013, 28, 981-989.	2.5	13
50	Evaluating 5-Nitrofurans as Trypanocidal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1638-1647.	1.4	32
51	Phenazine N,N ² -dioxide scaffold as selective hypoxic cytotoxin pharmacophore. Structural modifications looking for further DNA topoisomerase II-inhibition activity. <i>MedChemComm</i> , 2013, 4, 595.	3.5	14
52	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. <i>European Journal of Medicinal Chemistry</i> , 2013, 59, 64-74.	2.6	57
53	New oxidovanadium(IV) N-acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 20-27.	2.6	57
54	Oxidovanadium(IV) and dioxidovanadium(V) complexes of tridentate salicylaldehyde semicarbazones: Searching for prospective antitrypanosomal agents. <i>Journal of Inorganic Biochemistry</i> , 2013, 127, 150-160.	1.5	59

#	ARTICLE	IF	CITATIONS
55	A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective <i>Trypanosoma cruzi</i> growth inhibitors. Dalton Transactions, 2013, 42, 11900.	1.6	56
56	Identification of novel benzimidazole derivatives as anti- <i>Trypanosoma cruzi</i> agents: solid-phase synthesis, structure-activity relationships and molecular docking studies. Future Medicinal Chemistry, 2013, 5, 1719-1732.	1.1	8
57	Artificial Neural Networks Based on CODES Descriptors in Pharmacology: Identification of Novel Trypanocidal Drugs against Chagas Disease. Current Computer-Aided Drug Design, 2013, 9, 130-140.	0.8	1
58	Study of <i>Trypanosoma cruzi</i> epimastigote cell death by NMR-visible mobile lipid analysis. Parasitology, 2012, 139, 506-515.	0.7	9
59	Coordination of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides to antimony(III) as a strategy for anti- <i>Trypanosoma cruzi</i> activity improvement. Medicinal Chemistry Research, 2012, 21, 4120-4128.	1.1	5
60	Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as <i>Trypanosoma cruzi</i> -inhibitors: structural basis for their interactions with cruzipain. MedChemComm, 2012, 3, 90-101.	3.5	12
61	Quinoxaline derivatives: a patent review (2006 - present). Expert Opinion on Therapeutic Patents, 2012, 22, 1289-1302.	2.4	48
62	Bisphosphonate metal complexes as selective inhibitors of <i>Trypanosoma cruzi</i> farnesyl diphosphate synthase. Dalton Transactions, 2012, 41, 6468.	1.6	32
63	Activity on <i>Trypanosoma cruzi</i> , erythrocytes lysis and biologically relevant physicochemical properties of Pd(II) and Pt(II) complexes of thiosemicarbazones derived from 1-indanones. Journal of Inorganic Biochemistry, 2012, 117, 270-276.	1.5	16
64	Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds to Treat Sickle Cell Disease Symptoms. Part II: Furoxan Derivatives. Journal of Medicinal Chemistry, 2012, 55, 7583-7592.	2.9	49
65	Identification of Thioredoxin Glutathione Reductase Inhibitors That Kill Cestode and Trematode Parasites. PLoS ONE, 2012, 7, e35033.	1.1	34
66	Bioactive-guided Identification of Labdane Diterpenoids from Aerial Parts of <i>Aristeguetia glutinosa</i> as anti- <i>Trypanosoma cruzi</i> agents. Natural Product Communications, 2012, 7, 1934578X1200700.	0.2	2
67	Effect of complexation of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides with palladium and copper on their anti- <i>T. cruzi</i> activity. Medicinal Chemistry Research, 2012, 21, 1439-1444.	1.1	8
68	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	1.4	62
69	Reaction of isatin with alkylating agents with acidic methylenes. Tetrahedron Letters, 2012, 53, 2514-2517.	0.7	25
70	2-Acetylpyridine- and 2-benzoylpyridine-derived thiosemicarbazones and their antimony(III) complexes exhibit high anti-trypanosomal activity. Polyhedron, 2012, 31, 614-621.	1.0	36
71	Bioactive-guided identification of labdane diterpenoids from aerial parts of <i>Aristeguetia glutinosa</i> as anti- <i>Trypanosoma cruzi</i> agents. Natural Product Communications, 2012, 7, 1139-42.	0.2	7
72	3-Trifluoromethylquinoxaline <i>N,N'</i> -Dioxides as Anti- <i>Trypanosomatid</i> Agents. Identification of Optimal Anti- <i>T. cruzi</i> Agents and Mechanism of Action Studies. Journal of Medicinal Chemistry, 2011, 54, 3624-3636.	2.9	49

#	ARTICLE	IF	CITATIONS
73	Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 699-715.	2.4	13
74	Antiparasitic prodrug nifurtimox: revisiting its activation mechanism. <i>Future Microbiology</i> , 2011, 6, 847-850.	1.0	12
75	2D and 3D Quantitative Structure-Activity Relationship Studies for a Series of Phenazine <i>N,N</i> -Dioxides as Antitumour Agents. <i>Chemical Biology and Drug Design</i> , 2011, 78, 960-968.	1.5	7
76	6-Methylnitroarachidonate: A novel esterified nitroalkene that potently inhibits platelet aggregation and exerts cGMP-mediated vascular relaxation. <i>Free Radical Biology and Medicine</i> , 2011, 50, 411-418.	1.3	23
77	Thiosemicarbazones derived from 1-indanones as new anti- <i>Trypanosoma cruzi</i> agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6818-6826.	1.4	50
78	Potent 5-nitrofuranyl derivatives inhibitors of <i>Trypanosoma cruzi</i> growth: Electrochemical, spectroscopic and biological studies. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2011, 79, 312-319.	2.0	16
79	Genetic toxicology and preliminary <i>in vivo</i> studies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents. <i>Drug and Chemical Toxicology</i> , 2011, 34, 285-293.	1.2	10
80	Novel Phenazine 5,10-Dioxides Release H_2O_2 in Simulated Hypoxia and Induce Reduction of Tumour Volume <i>In Vivo</i> . <i>ISRN Pharmacology</i> , 2011, 2011, 1-11.	1.6	12
81	Coordination of nitro-thiosemicarbazones to ruthenium(II) as a strategy for anti-trypanosomal activity improvement. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 2847-2853.	2.6	33
82	Structural relationships in the solid state of the anti-chagas agent (E)-phenylethenylbenzofuroxan. <i>Molecular Diversity</i> , 2010, 14, 643-652.	2.1	4
83	Mode of action of Nifurtimox and N-oxide-containing heterocycles against <i>Trypanosoma cruzi</i> : Is oxidative stress involved?. <i>Biochemical Pharmacology</i> , 2010, 79, 1736-1745.	2.0	94
84	Risedronate metal complexes potentially active against Chagas disease. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 1252-1258.	1.5	58
85	New heteroaryl nitrones with spin trap properties: Identification of a 4-furoxanyl derivative with excellent properties to be used in biological systems. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 795-802.	1.4	25
86	Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4433-4440.	1.4	24
87	Identification of chalcones as <i>in vivo</i> liver monofunctional phase II enzymes inducers. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5391-5399.	1.4	27
88	Anti- <i>T. cruzi</i> activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4831-4835.	1.0	22
89	Synthesis and <i>in vitro</i> activity of limonene derivatives against <i>Leishmania</i> and <i>Trypanosoma</i> . <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 1524-1528.	2.6	40
90	Naftifine-analogues as anti- <i>Trypanosoma cruzi</i> agents. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 2154-2164.	2.6	33

#	ARTICLE	IF	CITATIONS
91	Structural modifications on the phenazine N,N-dioxide-scaffold looking for new selective hypoxic cytotoxins. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5362-5369.	2.6	24
92	Massive screening yields novel and selective <i>Trypanosoma cruzi</i> triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5767-5772.	2.6	47
93	Synthetic Medicinal Chemistry in Chagas™ Disease: Compounds at The Final Stage of ‘Hit-To-Lead’-Phase. <i>Pharmaceuticals</i> , 2010, 3, 810-838.	1.7	49
94	Development of second generation amidinohydrazones, thio- and semicarbazones as <i>Trypanosoma cruzi</i> -inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core scaffolds. <i>MedChemComm</i> , 2010, 1, 216.	3.5	34
95	Targets for Anti-T. <i>cruzi</i> Drugs in the Post-Genomic Era. <i>Current Enzyme Inhibition</i> , 2010, 6, 195-210.	0.3	7
96	Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs. <i>Molecules</i> , 2009, 14, 2256-2272.	1.7	41
97	5-Nitrofuranes and 5-nitrothiophenes with anti- <i>Trypanosoma cruzi</i> activity and ability to accumulate squalene. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7500-7509.	1.4	46
98	In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 1034-1040.	2.6	41
99	5-Nitro-2-furyl derivative actives against <i>Trypanosoma cruzi</i> : Preliminary in vivo studies. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3909-3914.	2.6	10
100	Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti- <i>Trypanosoma cruzi</i> activity. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 411-418.	1.5	75
101	Study of 5-nitroindazoles' anti- <i>Trypanosoma cruzi</i> mode of action: Electrochemical behaviour and ESR spectroscopic studies. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 1545-1553.	2.6	44
102	Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: Synthesis, biological evaluation, and mode of action studies. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4426-4433.	2.6	35
103	Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4937-4943.	2.6	41
104	Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 5055-5065.	2.6	33
105	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 641-652.	1.4	94
106	Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1623-1629.	1.4	25
107	New potent imidazoisoquinolinone derivatives as anti- <i>Trypanosoma cruzi</i> agents: Biological evaluation and structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1437-1444.	1.4	41
108	New potent 5-nitroindazole derivatives as inhibitors of <i>Trypanosoma cruzi</i> growth: Synthesis, biological evaluation, and mechanism of action studies. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 8186-8196.	1.4	41

#	ARTICLE	IF	CITATIONS
109	Interaction studies between human α -tocopherol transfer protein and nitric oxide donor tocopherol analogues with LDL-protective activity. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 8143-8148.	1.4	3
110	Cytotoxic, mutagenic and genotoxic effects of new anti- <i>T. cruzi</i> 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. <i>Toxicology Letters</i> , 2009, 190, 140-149.	0.4	31
111	New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 119-126.	1.5	58
112	Potent in vitro anti- <i>Trypanosoma cruzi</i> activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 723-735.	1.1	56
113	Evaluation of a new dendrimeric structure as prospective drugs carrier for intravenous administration of antichagasic active compounds. <i>Journal of Physical Organic Chemistry</i> , 2008, 21, 1079-1085.	0.9	21
114	Comparative spectroscopic and electrochemical study of nitroindazoles: 3-Alcoxy, 3-hydroxy and 3-oxo derivatives. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2008, 70, 557-563.	2.0	17
115	Development of a HPLC method for the determination of antichagasic phenylethenylbenzofuroxans and its major synthetic secondary products in the chemical production processes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 47, 88-94.	1.4	8
116	Platinum(II) metal complexes as potential anti- <i>Trypanosoma cruzi</i> agents. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 1033-1043.	1.5	74
117	Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 741-748.	2.6	26
118	4-Nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 939-948.	2.6	59
119	Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of <i>Trypanosoma cruzi</i> . <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1737-1741.	2.6	28
120	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2229-2237.	2.6	18
121	Heteroallyl-containing 5-nitrofuranes as new anti- <i>Trypanosoma cruzi</i> agents with a dual mechanism of action. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 569-577.	1.4	45
122	Imidazolidines as new anti- <i>Trypanosoma cruzi</i> agents: Biological evaluation and structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 2226-2234.	1.4	66
123	New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6995-7004.	1.4	47
124	Furoxan-, alkyl nitrate-derivatives and related compounds as anti-trypanosomatid agents: Mechanism of action studies. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7900-7907.	1.4	42
125	Arylethenylbenzofuroxan Derivatives as Drugs for Chagas Disease: Multigram Batch Synthesis using a Wittig-Boden Process. <i>Organic Process Research and Development</i> , 2008, 12, 156-162.	1.3	20
126	Convenient Route to Primary (Z)-Allyl Amines and Homologs. <i>Synthetic Communications</i> , 2008, 39, 29-47.	1.1	9

#	ARTICLE	IF	CITATIONS
127	Modeling anti-Trypanosoma cruzi Activity of N-Oxide Containing Heterocycles. Journal of Chemical Information and Modeling, 2008, 48, 213-219.	2.5	19
128	Antitumoral Effect of Phenazine $5,10$ -Dioxide Derivatives on Caco-2 Cells. Chemical Research in Toxicology, 2008, 21, 1578-1585.	1.7	25
129	Heteroarylnitrones as Drugs for Neurodegenerative Diseases: Synthesis, Neuroprotective Properties, and Free Radical Scavenger Properties. Journal of Medicinal Chemistry, 2008, 51, 6150-6159.	2.9	48
130	Differential Enzymatic Reductions Governing the Differential Hypoxia-Selective Cytotoxicities of Phenazine $5,10$ -Dioxides. Chemical Research in Toxicology, 2008, 21, 1900-1906.	1.7	28
131	Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1355-1383.	1.1	40
132	Quinoxaline $1,4$ -Dioxide and Phenazine $5,10$ -Dioxide. Chemistry and Biology. , 2007, , 179-211.		24
133	In Vivo Anti-Chagas Vinylthio-, Vinylsulfinyl-, and Vinylsulfonylbenzofuroxan Derivatives. Journal of Medicinal Chemistry, 2007, 50, 6004-6015.	2.9	35
134	Benzofuroxan and Furoxan. Chemistry and Biology. Topics in Heterocyclic Chemistry, 2007, , 265-308.	0.2	45
135	Interaction energies of nitrofurans with trypanothione reductase and glutathione reductase studied by molecular docking. Computational and Theoretical Chemistry, 2007, 818, 7-22.	1.5	10
136	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and structure-activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 2768-2781.	1.4	43
137	Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 3356-3367.	1.4	260
138	Second generation of α -tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization. Bioorganic and Medicinal Chemistry, 2007, 15, 6262-6272.	1.4	24
139	Structure of indazole N1-oxide derivatives studied by X-ray, theoretical methods, ^1H , ^{13}C , ^{15}N NMR and EI/MS. Journal of Molecular Structure, 2007, 871, 98-107.	1.8	8
140	2-Benzyl-2-methyl-2H-benzimidazole $1,3$ -dioxide derivatives: Spectroscopic and theoretical study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2007, 67, 540-549.	2.0	7
141	Vibrational spectra of palladium 5-nitrofuryl thiosemicarbazone complexes: Experimental and theoretical study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2007, 68, 341-348.	2.0	49
142	2H-Benzimidazole $1,3$ -Dioxide Derivatives: A New Family of Water-Soluble Anti-Trypanosomatid Agents. Journal of Medicinal Chemistry, 2006, 49, 3215-3224.	2.9	68
143	Novel Antitrypanosomal Agents Based on Palladium Nitrofurylthiosemicarbazone Complexes: DNA and Redox Metabolism as Potential Therapeutic Targets. Journal of Medicinal Chemistry, 2006, 49, 3322-3331.	2.9	157
144	Solubilization and Release Properties of Dendrimers. Evaluation as Prospective Drug Delivery Systems. Supramolecular Chemistry, 2006, 18, 633-643.	1.5	33

#	ARTICLE	IF	CITATIONS
145	New potent 5-nitrofuryl derivatives as inhibitors of <i>Trypanosoma cruzi</i> growth. 3D-QSAR (CoMFA) studies. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 457-466.	2.6	23
146	Design and evaluation of Co^{3+} mixed ligand oxorhenium and oxotechnetium complexes bearing a nitroaromatic group with potential application in nuclear medicine oncology. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 1144-1152.	2.6	27
147	Nitrofurylsemicarbazone Rhenium and Ruthenium Complexes as Anti-trypanosomal Agents. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 1231-1239.	2.6	35
148	Indazole N-oxide derivatives as antiprotozoal agents: Synthesis, biological evaluation and mechanism of action studies. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3467-3480.	1.4	78
149	Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by complexation with vanadium. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 5503-5509.	1.4	76
150	ESR and electrochemical study of 5-nitroindazole derivatives with antiprotozoal activity. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2006, 63, 36-42.	2.0	18
151	Novel vanadyl complexes with quinoxaline N1,N4-dioxide derivatives as potent in vitro insulin-mimetic compounds. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 281-287.	1.5	29
152	Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1358-1367.	1.5	22
153	Theoretical study on 5-nitrofuryl thiosemicarbazone radicals electronic properties. <i>Computational and Theoretical Chemistry</i> , 2006, 770, 125-129.	1.5	5
154	Synthesis and Characterization of Thiol Containing Furoxan Derivatives as Coligands for the Preparation of Potential Bioreductive Radiopharmaceuticals. <i>Archiv Der Pharmazie</i> , 2006, 339, 59-66.	2.1	12
155	Development of Hypoxia Selective Cytotoxins for Cancer Treatment: An Update. <i>Medicinal Chemistry</i> , 2006, 2, 315-327.	0.7	15
156	$\text{Pd}(\text{thiosaccharinato})_2 \cdot 2\text{H}_2\text{O}$, the first thiosaccharinato complex of a platinum-group metal. <i>Journal of Coordination Chemistry</i> , 2006, 59, 101-106.	0.8	16
157	One pot synthesis of benzyltriphenylphosphonium acetates from the corresponding activated benzylic alcohols. <i>Arkivoc</i> , 2006, 2006, 128-136.	0.3	11
158	Electrochemical and ESR study of 5-nitrofuryl-containing thiosemicarbazones antiprotozoal drugs. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2005, 61, 2933-2938.	2.0	26
159	Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of $[\text{VO}_2(5\text{-bromosalicylaldehyde})_2] \cdot 2\text{H}_2\text{O}$. <i>Journal of Inorganic Biochemistry</i> , 2005, 95, 144-150.	1.4	10
160	Chemo-selective hydrolysis of the iminic moiety in salicylaldehyde semicarbazone promoted by ruthenium. <i>Inorganica Chimica Acta</i> , 2005, 358, 3065-3074.	1.2	17
161	Synthesis and biological properties of new 5-nitroindazole derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3197-3207.	1.4	63
162	Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: Substituents-clustering methodology in the search for new active compounds. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6324-6335.	1.4	49

#	ARTICLE	IF	CITATIONS
163	Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 5787-5796.	1.4	31
164	New potent 5-substituted benzofuroxans as inhibitors of <i>Trypanosoma cruzi</i> growth: Quantitative structure-activity relationship studies. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6336-6346.	1.4	36
165	Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 473-480.	2.6	58
166	New Synthetic Approach for the Preparation of Imidazole N3-Oxides.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
167	Relationship Between Physicochemical Properties and Herbicidal Activity of 1,2,5-Oxadiazole N-Oxide Derivatives. <i>Molecules</i> , 2005, 10, 1197-1208.	1.7	11
168	Preparation of phenazine N5,N10-dioxides: Effects of benzofuroxan substituents in the outcome of their expansion reaction with phenolates. <i>Journal of the Brazilian Chemical Society</i> , 2005, 16, 1290-1296.	0.6	20
169	Imidazole and Benzimidazole Derivatives as Chemotherapeutic Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 409-424.	1.1	378
170	Novel Benzo[1,2-c]1,2,5-Oxadiazole N-Oxide Derivatives as Antichagasic Agents: Chemical and Biological Studies. <i>Letters in Drug Design and Discovery</i> , 2005, 2, 294-301.	0.4	28
171	Pharmacological Properties of Indazole Derivatives: Recent Developments. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 869-878.	1.1	274
172	Phenazine 5,10-Dioxide Derivatives as Hypoxic Selective Cytotoxins. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 21-23.	2.9	52
173	Mass spectrometry of 1,2,5-oxadiazole N-oxide derivatives: use of deuterated analogues in fragmentation pattern studies. <i>Journal of the Brazilian Chemical Society</i> , 2004, 15, 232-240.	0.6	11
174	Cytotoxicity of furoxans: quantitative structure-activity relationships study. <i>Il Farmaco</i> , 2004, 59, 405-412.	0.9	23
175	1, 2, 4-TriazineN-oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part II.. <i>Archiv Der Pharmazie</i> , 2004, 337, 247-258.	2.1	15
176	1, 2, 4-TriazineN-oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part III. <i>Archiv Der Pharmazie</i> , 2004, 337, 271-280.	2.1	19
177	Novel Antiprotozoal Products: Imidazole and BenzimidazoleN-Oxide Derivatives and Related Compounds. <i>Archiv Der Pharmazie</i> , 2004, 337, 259-270.	2.1	68
178	New Vanadium(V) Complexes with Salicylaldehyde Semicarbazone Derivatives: Synthesis, Characterization, and in vitro Insulin-Mimetic Activity Crystal Structure of [VVO ₂ (salicylaldehyde) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5		
179	Cytotoxicity of Furoxans: Quantitative Structure-Activity Relationships Study.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
180	Novel Antiprotozoal Products: Imidazole and Benzimidazole N-Oxide Derivatives and Related Compounds.. <i>ChemInform</i> , 2004, 35, no.	0.1	0

#	ARTICLE	IF	CITATIONS
181	1,2,4-Triazine N-Oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part 2.. ChemInform, 2004, 35, no.	0.1	0
182	1,2,4-Triazine N-Oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part 3.. ChemInform, 2004, 35, no.	0.1	0
183	Design, Synthesis and Biological Evaluation of New Potent 5-Nitrofuryl Derivatives as anti-Trypanosoma cruzi Agents. Studies of Trypanothione Binding Site of Trypanothione Reductase as Target for Rational Design.. ChemInform, 2004, 35, no.	0.1	0
184	In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorganic and Medicinal Chemistry, 2004, 12, 4885-4893.	1.4	118
185	Ruthenium (II) nitrofurylsemicarbazone complexes: new DNA binding agents. European Journal of Medicinal Chemistry, 2004, 39, 377-382.	2.6	32
186	Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. European Journal of Medicinal Chemistry, 2004, 39, 421-431.	2.6	56
187	Quinoxaline N , N -dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi . Structure-activity relationships. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3835-3839.	1.0	79
188	Tautomerism and Reactivity in HeterocyclicN-Oxides. A Spectroscopic and Theoretical Study of BenzimidazoleN-Oxide Derivatives (N-Hydroxybenzimidazoles). Journal of Physical Chemistry A, 2004, 108, 11241-11248.	1.1	25
189	Synthesis and characterization of new ruthenium complexes with active ligands against Chagas' disease. Inorganica Chimica Acta, 2003, 344, 85-94.	1.2	53
190	Electrochemical and microsomal production of free radicals from 1,2,5-oxadiazole N-oxide as potential antiprotozoal drugs. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2003, 59, 69-74.	2.0	33
191	ESR Spin Trapping Studies of Free Radicals Generated from Nitrofuran Derivative Analogues of Nifurtimox by Electrochemical and Trypanosoma cruzi Reduction. Free Radical Research, 2003, 37, 993-1001.	1.5	46
192	ESR AND SPIN TRAPPING STUDIES OF TWO NEW POTENTIAL NTITRYPANOSOMAL DRUGS. Journal of the Chilean Chemical Society, 2003, 48, .	0.5	24
193	Characterization of [ReO(Tetramethylthiourea)4](PF6)3 in Solution: Electrochemical, NMR and Ligand Substitution Studies. Journal of Coordination Chemistry, 2002, 55, 1441-1453.	0.8	5
194	Chemotherapy of Chagas Disease: Status and New Developments. Current Topics in Medicinal Chemistry, 2002, 2, 1187-1213.	1.0	129
195	Benzo[1, 2-c]1, 2, 5-oxadiazole N-Oxide Derivatives as Potential Antitrypanosomal Drugs. Structure-Activity Relationships. Part II. Archiv Der Pharmazie, 2002, 335, 15-21.	2.1	37
196	1,2,5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: synthesis and biological evaluation. Part IV. European Journal of Medicinal Chemistry, 2001, 36, 771-782.	2.6	59
197	N-Oxides as Hypoxia Selective Cytotoxins. Mini-Reviews in Medicinal Chemistry, 2001, 1, 219-231.	1.1	43
198	Synthesis and Biological Evaluation of 1,2,5-OxadiazoleN-Oxide Derivatives as Potential Hypoxic Cytotoxins and DNA-Binders. Archiv Der Pharmazie, 2000, 333, 387-393.	2.1	17

#	ARTICLE	IF	CITATIONS
199	Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. Structure-activity relationships. European Journal of Medicinal Chemistry, 2000, 35, 343-350.	2.6	92
200	Synthesis and Herbicidal Activity of N-Oxide Derivatives. Journal of Agricultural and Food Chemistry, 2000, 48, 2995-3002.	2.4	54
201	1,2,5-Oxadiazole N-Oxide Derivatives and Related Compounds as Potential Antitrypanosomal Drugs: A Structure-Activity Relationships. Journal of Medicinal Chemistry, 1999, 42, 1941-1950.	2.9	136
202	Preparation of Enamines from the Condensation of Glycine Esters with Nitro-Heterocyclic Aldehydes. Heterocycles, 1997, 45, 2023.	0.4	12
203	New hypoxia-selective cytotoxines derived from quinoxaline 1,4-dioxides. Journal of Heterocyclic Chemistry, 1995, 32, 1213-1217.	1.4	30
204	Hypoxia-Selective Agents Derived from 2-Quinoxalinecarbonitrile 1,4-Di-N-oxides. 2. Journal of Medicinal Chemistry, 1995, 38, 4488-4494.	2.9	117